Integration of protein L-immobilized epoxy magnetic bead capture with LC-MS/MS for therapeutic monoclonal antibody quantification in serum

In recent years, there has been a growing interest in the thriving monoclonal antibody (mAb) industry due to the wide utilization of mAbs in clinical therapies. Robust and accurate bioanalytical methods are required to enable fast quantification of mAbs in biological matrices, especially in the cont...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Analytical methods 2024-06, Vol.16 (23), p.372-3731
Hauptverfasser: Cao, Rongrong, Xu, Songlin, Yu, Zhirui, Xu, Liang, Ge, Zhiqiang, Huo, Qianyu, Zhu, Guoqing, Qiao, Bin
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 3731
container_issue 23
container_start_page 372
container_title Analytical methods
container_volume 16
creator Cao, Rongrong
Xu, Songlin
Yu, Zhirui
Xu, Liang
Ge, Zhiqiang
Huo, Qianyu
Zhu, Guoqing
Qiao, Bin
description In recent years, there has been a growing interest in the thriving monoclonal antibody (mAb) industry due to the wide utilization of mAbs in clinical therapies. Robust and accurate bioanalytical methods are required to enable fast quantification of mAbs in biological matrices, especially in the context of pharmacokinetics (PKs)/pharmacodynamics (PDs) and therapeutic drug monitoring (TDM) studies. In this investigation, we presented a novel immuno-magnetic capture coupled with a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method designed for the quantification of immunoglobulin G-kappa-based mAbs in biological fluids. The immunoaffinity absorbent for mAb drug purification was meticulously crafted by immobilizing protein L onto monosize, magnetic poly(glycidyl methacrylate) (m-pGMA) beads, synthesized through dispersion polymerization. The microspheres were acquired with an average size of 1.6 μm, and the optimal binding of mAbs from the aqueous mAb solution was determined to be 45.82 mg g −1 . The quantification of mAbs in 10 μL serum samples was achieved through affinity purification using m-pGMA@protein L beads (employing rituximab as an internal standard (IS)), on-bead reduction, and rapid tryptic digestion. Remarkably, the entire process, taking less than 2.5 hours, held significant potential for simplifying pretreatment procedures and minimizing analytical time. Furthermore, the developed method underwent validation in accordance with the European Medicines Agency (EMA) guidelines. The assay demonstrated commendable linearity within the 2-400 μg mL −1 range for both daratumumab and pembrolizumab. Intra- and inter-assay coefficients of variation fell within the range of 0.7% to 13.4%, meeting established acceptance criteria. Other validation parameters also conformed to regulatory standards. Ultimately, the efficacy of the method was substantiated in a pharmacokinetic study following a single-dose intravenous administration to mice, underscoring its applicability and reliability in real-world scenarios. Procedures for integrating protein L-immobilized magnetic bead capture with LC-MS/MS for mAb quantification in mouse serum.
doi_str_mv 10.1039/d4ay00433g
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_38808588</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3067382814</sourcerecordid><originalsourceid>FETCH-LOGICAL-c226t-5b4f07ebed00292cec93e2f26acf0c7c5e349147d02a50b5253934eb6ca9bc5c3</originalsourceid><addsrcrecordid>eNpd0UtP3DAQB3ALFcFCe-FOZakXhBTwIw_7iLa8pEU9bHvoKbKdyWKUxFnbUbt8BD412V1YJE4z0vw0o9EfoRNKLijh8rJK1YqQlPPFHprQIpOJzAv5Zdfn5BAdhfBESC55Tg_QIReCiEyICXq57yIsvIrWddjVuPcugu3wLLFt67Rt7DNUGHr3f4VbteggWoM1qAob1cfBA_5n4yOeTZOH-eXDHNfO4_gIXvUwrGnrOmca16kGqy5a7aoVXg7rtrZme3W8FsAP7Ve0X6smwLe3eoz-3Fz_nt4ls1-399OrWWIYy2OS6bQmBWioCGGSGTCSA6tZrkxNTGEy4KmkaVERpjKiM5ZxyVPQuVFSm8zwY3S23Tv-uhwgxLK1wUDTqA7cEEpOcloILigf6Y9P9MkNfnxmowoumKDpqM63yngXgoe67L1tlV-VlJTrhMqf6dXfTUK3I_7-tnLQLVQ7-h7JCE63wAezm35EzF8B0H6XrQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3067382814</pqid></control><display><type>article</type><title>Integration of protein L-immobilized epoxy magnetic bead capture with LC-MS/MS for therapeutic monoclonal antibody quantification in serum</title><source>MEDLINE</source><source>Royal Society Of Chemistry Journals 2008-</source><creator>Cao, Rongrong ; Xu, Songlin ; Yu, Zhirui ; Xu, Liang ; Ge, Zhiqiang ; Huo, Qianyu ; Zhu, Guoqing ; Qiao, Bin</creator><creatorcontrib>Cao, Rongrong ; Xu, Songlin ; Yu, Zhirui ; Xu, Liang ; Ge, Zhiqiang ; Huo, Qianyu ; Zhu, Guoqing ; Qiao, Bin</creatorcontrib><description>In recent years, there has been a growing interest in the thriving monoclonal antibody (mAb) industry due to the wide utilization of mAbs in clinical therapies. Robust and accurate bioanalytical methods are required to enable fast quantification of mAbs in biological matrices, especially in the context of pharmacokinetics (PKs)/pharmacodynamics (PDs) and therapeutic drug monitoring (TDM) studies. In this investigation, we presented a novel immuno-magnetic capture coupled with a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method designed for the quantification of immunoglobulin G-kappa-based mAbs in biological fluids. The immunoaffinity absorbent for mAb drug purification was meticulously crafted by immobilizing protein L onto monosize, magnetic poly(glycidyl methacrylate) (m-pGMA) beads, synthesized through dispersion polymerization. The microspheres were acquired with an average size of 1.6 μm, and the optimal binding of mAbs from the aqueous mAb solution was determined to be 45.82 mg g −1 . The quantification of mAbs in 10 μL serum samples was achieved through affinity purification using m-pGMA@protein L beads (employing rituximab as an internal standard (IS)), on-bead reduction, and rapid tryptic digestion. Remarkably, the entire process, taking less than 2.5 hours, held significant potential for simplifying pretreatment procedures and minimizing analytical time. Furthermore, the developed method underwent validation in accordance with the European Medicines Agency (EMA) guidelines. The assay demonstrated commendable linearity within the 2-400 μg mL −1 range for both daratumumab and pembrolizumab. Intra- and inter-assay coefficients of variation fell within the range of 0.7% to 13.4%, meeting established acceptance criteria. Other validation parameters also conformed to regulatory standards. Ultimately, the efficacy of the method was substantiated in a pharmacokinetic study following a single-dose intravenous administration to mice, underscoring its applicability and reliability in real-world scenarios. Procedures for integrating protein L-immobilized magnetic bead capture with LC-MS/MS for mAb quantification in mouse serum.</description><identifier>ISSN: 1759-9660</identifier><identifier>ISSN: 1759-9679</identifier><identifier>EISSN: 1759-9679</identifier><identifier>DOI: 10.1039/d4ay00433g</identifier><identifier>PMID: 38808588</identifier><language>eng</language><publisher>England: Royal Society of Chemistry</publisher><subject>Acceptance criteria ; Animals ; Antibodies, Monoclonal - blood ; Antibodies, Monoclonal - chemistry ; Antibodies, Monoclonal - immunology ; Antibodies, Monoclonal - pharmacokinetics ; Chromatography, Liquid - methods ; Coefficient of variation ; Humans ; IgG antibody ; Immunoglobulin G ; Immunomagnetic Separation - methods ; Intravenous administration ; Liquid chromatography ; Liquid Chromatography-Mass Spectrometry ; Mass spectrometry ; Mass spectroscopy ; Mice ; Microspheres ; Monoclonal antibodies ; Pembrolizumab ; Pharmacodynamics ; Pharmacokinetics ; Polymethacrylic Acids - chemistry ; Protein L ; Protein purification ; Proteins ; Purification ; Rituximab ; Tandem Mass Spectrometry - methods</subject><ispartof>Analytical methods, 2024-06, Vol.16 (23), p.372-3731</ispartof><rights>Copyright Royal Society of Chemistry 2024</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c226t-5b4f07ebed00292cec93e2f26acf0c7c5e349147d02a50b5253934eb6ca9bc5c3</cites><orcidid>0000-0002-2731-2018 ; 0000-0002-8297-3353 ; 0000-0003-2210-476X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38808588$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cao, Rongrong</creatorcontrib><creatorcontrib>Xu, Songlin</creatorcontrib><creatorcontrib>Yu, Zhirui</creatorcontrib><creatorcontrib>Xu, Liang</creatorcontrib><creatorcontrib>Ge, Zhiqiang</creatorcontrib><creatorcontrib>Huo, Qianyu</creatorcontrib><creatorcontrib>Zhu, Guoqing</creatorcontrib><creatorcontrib>Qiao, Bin</creatorcontrib><title>Integration of protein L-immobilized epoxy magnetic bead capture with LC-MS/MS for therapeutic monoclonal antibody quantification in serum</title><title>Analytical methods</title><addtitle>Anal Methods</addtitle><description>In recent years, there has been a growing interest in the thriving monoclonal antibody (mAb) industry due to the wide utilization of mAbs in clinical therapies. Robust and accurate bioanalytical methods are required to enable fast quantification of mAbs in biological matrices, especially in the context of pharmacokinetics (PKs)/pharmacodynamics (PDs) and therapeutic drug monitoring (TDM) studies. In this investigation, we presented a novel immuno-magnetic capture coupled with a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method designed for the quantification of immunoglobulin G-kappa-based mAbs in biological fluids. The immunoaffinity absorbent for mAb drug purification was meticulously crafted by immobilizing protein L onto monosize, magnetic poly(glycidyl methacrylate) (m-pGMA) beads, synthesized through dispersion polymerization. The microspheres were acquired with an average size of 1.6 μm, and the optimal binding of mAbs from the aqueous mAb solution was determined to be 45.82 mg g −1 . The quantification of mAbs in 10 μL serum samples was achieved through affinity purification using m-pGMA@protein L beads (employing rituximab as an internal standard (IS)), on-bead reduction, and rapid tryptic digestion. Remarkably, the entire process, taking less than 2.5 hours, held significant potential for simplifying pretreatment procedures and minimizing analytical time. Furthermore, the developed method underwent validation in accordance with the European Medicines Agency (EMA) guidelines. The assay demonstrated commendable linearity within the 2-400 μg mL −1 range for both daratumumab and pembrolizumab. Intra- and inter-assay coefficients of variation fell within the range of 0.7% to 13.4%, meeting established acceptance criteria. Other validation parameters also conformed to regulatory standards. Ultimately, the efficacy of the method was substantiated in a pharmacokinetic study following a single-dose intravenous administration to mice, underscoring its applicability and reliability in real-world scenarios. Procedures for integrating protein L-immobilized magnetic bead capture with LC-MS/MS for mAb quantification in mouse serum.</description><subject>Acceptance criteria</subject><subject>Animals</subject><subject>Antibodies, Monoclonal - blood</subject><subject>Antibodies, Monoclonal - chemistry</subject><subject>Antibodies, Monoclonal - immunology</subject><subject>Antibodies, Monoclonal - pharmacokinetics</subject><subject>Chromatography, Liquid - methods</subject><subject>Coefficient of variation</subject><subject>Humans</subject><subject>IgG antibody</subject><subject>Immunoglobulin G</subject><subject>Immunomagnetic Separation - methods</subject><subject>Intravenous administration</subject><subject>Liquid chromatography</subject><subject>Liquid Chromatography-Mass Spectrometry</subject><subject>Mass spectrometry</subject><subject>Mass spectroscopy</subject><subject>Mice</subject><subject>Microspheres</subject><subject>Monoclonal antibodies</subject><subject>Pembrolizumab</subject><subject>Pharmacodynamics</subject><subject>Pharmacokinetics</subject><subject>Polymethacrylic Acids - chemistry</subject><subject>Protein L</subject><subject>Protein purification</subject><subject>Proteins</subject><subject>Purification</subject><subject>Rituximab</subject><subject>Tandem Mass Spectrometry - methods</subject><issn>1759-9660</issn><issn>1759-9679</issn><issn>1759-9679</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpd0UtP3DAQB3ALFcFCe-FOZakXhBTwIw_7iLa8pEU9bHvoKbKdyWKUxFnbUbt8BD412V1YJE4z0vw0o9EfoRNKLijh8rJK1YqQlPPFHprQIpOJzAv5Zdfn5BAdhfBESC55Tg_QIReCiEyICXq57yIsvIrWddjVuPcugu3wLLFt67Rt7DNUGHr3f4VbteggWoM1qAob1cfBA_5n4yOeTZOH-eXDHNfO4_gIXvUwrGnrOmca16kGqy5a7aoVXg7rtrZme3W8FsAP7Ve0X6smwLe3eoz-3Fz_nt4ls1-399OrWWIYy2OS6bQmBWioCGGSGTCSA6tZrkxNTGEy4KmkaVERpjKiM5ZxyVPQuVFSm8zwY3S23Tv-uhwgxLK1wUDTqA7cEEpOcloILigf6Y9P9MkNfnxmowoumKDpqM63yngXgoe67L1tlV-VlJTrhMqf6dXfTUK3I_7-tnLQLVQ7-h7JCE63wAezm35EzF8B0H6XrQ</recordid><startdate>20240613</startdate><enddate>20240613</enddate><creator>Cao, Rongrong</creator><creator>Xu, Songlin</creator><creator>Yu, Zhirui</creator><creator>Xu, Liang</creator><creator>Ge, Zhiqiang</creator><creator>Huo, Qianyu</creator><creator>Zhu, Guoqing</creator><creator>Qiao, Bin</creator><general>Royal Society of Chemistry</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QF</scope><scope>7QO</scope><scope>7QQ</scope><scope>7SE</scope><scope>7SR</scope><scope>7U5</scope><scope>8BQ</scope><scope>8FD</scope><scope>FR3</scope><scope>H8G</scope><scope>JG9</scope><scope>L7M</scope><scope>P64</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-2731-2018</orcidid><orcidid>https://orcid.org/0000-0002-8297-3353</orcidid><orcidid>https://orcid.org/0000-0003-2210-476X</orcidid></search><sort><creationdate>20240613</creationdate><title>Integration of protein L-immobilized epoxy magnetic bead capture with LC-MS/MS for therapeutic monoclonal antibody quantification in serum</title><author>Cao, Rongrong ; Xu, Songlin ; Yu, Zhirui ; Xu, Liang ; Ge, Zhiqiang ; Huo, Qianyu ; Zhu, Guoqing ; Qiao, Bin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c226t-5b4f07ebed00292cec93e2f26acf0c7c5e349147d02a50b5253934eb6ca9bc5c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Acceptance criteria</topic><topic>Animals</topic><topic>Antibodies, Monoclonal - blood</topic><topic>Antibodies, Monoclonal - chemistry</topic><topic>Antibodies, Monoclonal - immunology</topic><topic>Antibodies, Monoclonal - pharmacokinetics</topic><topic>Chromatography, Liquid - methods</topic><topic>Coefficient of variation</topic><topic>Humans</topic><topic>IgG antibody</topic><topic>Immunoglobulin G</topic><topic>Immunomagnetic Separation - methods</topic><topic>Intravenous administration</topic><topic>Liquid chromatography</topic><topic>Liquid Chromatography-Mass Spectrometry</topic><topic>Mass spectrometry</topic><topic>Mass spectroscopy</topic><topic>Mice</topic><topic>Microspheres</topic><topic>Monoclonal antibodies</topic><topic>Pembrolizumab</topic><topic>Pharmacodynamics</topic><topic>Pharmacokinetics</topic><topic>Polymethacrylic Acids - chemistry</topic><topic>Protein L</topic><topic>Protein purification</topic><topic>Proteins</topic><topic>Purification</topic><topic>Rituximab</topic><topic>Tandem Mass Spectrometry - methods</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cao, Rongrong</creatorcontrib><creatorcontrib>Xu, Songlin</creatorcontrib><creatorcontrib>Yu, Zhirui</creatorcontrib><creatorcontrib>Xu, Liang</creatorcontrib><creatorcontrib>Ge, Zhiqiang</creatorcontrib><creatorcontrib>Huo, Qianyu</creatorcontrib><creatorcontrib>Zhu, Guoqing</creatorcontrib><creatorcontrib>Qiao, Bin</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Aluminium Industry Abstracts</collection><collection>Biotechnology Research Abstracts</collection><collection>Ceramic Abstracts</collection><collection>Corrosion Abstracts</collection><collection>Engineered Materials Abstracts</collection><collection>Solid State and Superconductivity Abstracts</collection><collection>METADEX</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Copper Technical Reference Library</collection><collection>Materials Research Database</collection><collection>Advanced Technologies Database with Aerospace</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Analytical methods</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cao, Rongrong</au><au>Xu, Songlin</au><au>Yu, Zhirui</au><au>Xu, Liang</au><au>Ge, Zhiqiang</au><au>Huo, Qianyu</au><au>Zhu, Guoqing</au><au>Qiao, Bin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Integration of protein L-immobilized epoxy magnetic bead capture with LC-MS/MS for therapeutic monoclonal antibody quantification in serum</atitle><jtitle>Analytical methods</jtitle><addtitle>Anal Methods</addtitle><date>2024-06-13</date><risdate>2024</risdate><volume>16</volume><issue>23</issue><spage>372</spage><epage>3731</epage><pages>372-3731</pages><issn>1759-9660</issn><issn>1759-9679</issn><eissn>1759-9679</eissn><abstract>In recent years, there has been a growing interest in the thriving monoclonal antibody (mAb) industry due to the wide utilization of mAbs in clinical therapies. Robust and accurate bioanalytical methods are required to enable fast quantification of mAbs in biological matrices, especially in the context of pharmacokinetics (PKs)/pharmacodynamics (PDs) and therapeutic drug monitoring (TDM) studies. In this investigation, we presented a novel immuno-magnetic capture coupled with a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method designed for the quantification of immunoglobulin G-kappa-based mAbs in biological fluids. The immunoaffinity absorbent for mAb drug purification was meticulously crafted by immobilizing protein L onto monosize, magnetic poly(glycidyl methacrylate) (m-pGMA) beads, synthesized through dispersion polymerization. The microspheres were acquired with an average size of 1.6 μm, and the optimal binding of mAbs from the aqueous mAb solution was determined to be 45.82 mg g −1 . The quantification of mAbs in 10 μL serum samples was achieved through affinity purification using m-pGMA@protein L beads (employing rituximab as an internal standard (IS)), on-bead reduction, and rapid tryptic digestion. Remarkably, the entire process, taking less than 2.5 hours, held significant potential for simplifying pretreatment procedures and minimizing analytical time. Furthermore, the developed method underwent validation in accordance with the European Medicines Agency (EMA) guidelines. The assay demonstrated commendable linearity within the 2-400 μg mL −1 range for both daratumumab and pembrolizumab. Intra- and inter-assay coefficients of variation fell within the range of 0.7% to 13.4%, meeting established acceptance criteria. Other validation parameters also conformed to regulatory standards. Ultimately, the efficacy of the method was substantiated in a pharmacokinetic study following a single-dose intravenous administration to mice, underscoring its applicability and reliability in real-world scenarios. Procedures for integrating protein L-immobilized magnetic bead capture with LC-MS/MS for mAb quantification in mouse serum.</abstract><cop>England</cop><pub>Royal Society of Chemistry</pub><pmid>38808588</pmid><doi>10.1039/d4ay00433g</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0002-2731-2018</orcidid><orcidid>https://orcid.org/0000-0002-8297-3353</orcidid><orcidid>https://orcid.org/0000-0003-2210-476X</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1759-9660
ispartof Analytical methods, 2024-06, Vol.16 (23), p.372-3731
issn 1759-9660
1759-9679
1759-9679
language eng
recordid cdi_pubmed_primary_38808588
source MEDLINE; Royal Society Of Chemistry Journals 2008-
subjects Acceptance criteria
Animals
Antibodies, Monoclonal - blood
Antibodies, Monoclonal - chemistry
Antibodies, Monoclonal - immunology
Antibodies, Monoclonal - pharmacokinetics
Chromatography, Liquid - methods
Coefficient of variation
Humans
IgG antibody
Immunoglobulin G
Immunomagnetic Separation - methods
Intravenous administration
Liquid chromatography
Liquid Chromatography-Mass Spectrometry
Mass spectrometry
Mass spectroscopy
Mice
Microspheres
Monoclonal antibodies
Pembrolizumab
Pharmacodynamics
Pharmacokinetics
Polymethacrylic Acids - chemistry
Protein L
Protein purification
Proteins
Purification
Rituximab
Tandem Mass Spectrometry - methods
title Integration of protein L-immobilized epoxy magnetic bead capture with LC-MS/MS for therapeutic monoclonal antibody quantification in serum
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T18%3A06%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Integration%20of%20protein%20L-immobilized%20epoxy%20magnetic%20bead%20capture%20with%20LC-MS/MS%20for%20therapeutic%20monoclonal%20antibody%20quantification%20in%20serum&rft.jtitle=Analytical%20methods&rft.au=Cao,%20Rongrong&rft.date=2024-06-13&rft.volume=16&rft.issue=23&rft.spage=372&rft.epage=3731&rft.pages=372-3731&rft.issn=1759-9660&rft.eissn=1759-9679&rft_id=info:doi/10.1039/d4ay00433g&rft_dat=%3Cproquest_pubme%3E3067382814%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3067382814&rft_id=info:pmid/38808588&rfr_iscdi=true